Effects of terguride, ropinirole, and acetyl-L-carnitine on methamphetamine withdrawal in the rat

被引:26
作者
Hoefer, Michael E. [1 ]
Voskanian, Steven J. [1 ]
Koob, George F. [1 ]
Pulvirenti, Luigi [1 ]
机构
[1] Scripps Res Inst, Mol & Integrat Neurosci Dept, La Jolla, CA 92037 USA
关键词
dopamine; partial agonist; methamphetamine; acetyl-L-carnitine; withdrawal; drug addiction;
D O I
10.1016/j.pbb.2006.02.023
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Withdrawal from psychostimulants, including methamphetamine, induces a depressive state associated with lethargy, dysphoria, hyperphagia and psychomotor retardation. Previous work with repeated administration of amphetamine in rats has shown that amphetamine withdrawal produces decreased motivation to work for a non-drug reward, and this withdrawal is reversed by administration of a dopamine partial agonist. The purpose of the present study was to examine decreased motivation to work for a non-drug reward during methamphetamine withdrawal and explore the effects of a dopamine agonist, dopamine partial agonist, and indirect monoamine agonist on methamphetamine withdrawal. During withdrawal from repeated methamphetamine administration, rats showed reduced responding for a sweet solution in a progressive-ratio schedule of reinforcement, and this effect was significantly more pronounced than previously observed with amphetamine. Repeated systemic treatment with the dopamine partial agonist terguride (0.2 and 0.4 mg/kg, i.p., twice daily), the full dopamine agonist ropinirole (1 mg/kg, i.p., twice daily), and acetyl-L-carnitine (60 and 100 mg/kg, i.p.), a compound with a potential antidepressant effect, during methamphetamine withdrawal restored responding for the sweet solution, suggesting that these drugs may represent potential therapeutic strategies for the treatment of methamphetamine addiction during the withdrawal phase. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:403 / 409
页数:7
相关论文
共 51 条
[1]  
[Anonymous], 1989, NEW TRENDS CLIN NEUR
[2]   Withdrawal following repeated exposure to d-amphetamine decreases responding for a sucrose solution as measured by a progressive ratio schedule of reinforcement [J].
Barr, AM ;
Phillips, AG .
PSYCHOPHARMACOLOGY, 1999, 141 (01) :99-106
[3]   COCAINE REINFORCED PROGRESSIVE RATIO PERFORMANCE IN RHESUS-MONKEY [J].
BEDFORD, JA ;
BAILEY, LP ;
WILSON, MC .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1978, 9 (05) :631-638
[4]   Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors [J].
Bianchetti, A ;
Rozzini, R ;
Trabucchi, M .
CURRENT MEDICAL RESEARCH AND OPINION, 2003, 19 (04) :350-353
[5]  
BONAVITA E, 1986, INT J CLIN PHARM TH, V24, P511
[6]   Ropinirole in treatment-resistant depression: A 16-week pilot study [J].
Cassano, P ;
Lattanzi, L ;
Fava, MI ;
Navari, S ;
Battistini, G ;
Abelli, M ;
Cassano, GB .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2005, 50 (06) :357-360
[7]   BEHAVIORAL PROFILE OF PARTIAL D2 DOPAMINE RECEPTOR AGONISTS .1. ATYPICAL INHIBITION OF D-AMPHETAMINE-INDUCED LOCOMOTOR HYPERACTIVITY AND STEREOTYPY [J].
CLARK, D ;
FURMIDGE, LJ ;
PETRY, N ;
TONG, ZY ;
ERICSSON, M ;
JOHNSON, D .
PSYCHOPHARMACOLOGY, 1991, 105 (03) :381-392
[8]   Treatment of methamphetamine abuse: research findings and clinical directions [J].
Cretzmeyer, M ;
Sarrazin, MV ;
Huber, DL ;
Block, RI ;
Hall, JA .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2003, 24 (03) :267-277
[9]   Buprenorphine in the treatment of opioid dependence [J].
Davids, E ;
Gastpar, M .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 (03) :209-216
[10]   Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy: A long-term, randomised, double-blind, placebo-controlled study [J].
De Grandis D. ;
Minardi C. .
Drugs in R & D, 2002, 3 (4) :223-231